1. Home
  2. MANH vs GKOS Comparison

MANH vs GKOS Comparison

Compare MANH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Associates Inc.

MANH

Manhattan Associates Inc.

HOLD

Current Price

$191.12

Market Cap

8.2B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$167.16

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MANH
GKOS
Founded
1990
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
9.0B
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
MANH
GKOS
Price
$191.12
$167.16
Analyst Decision
Buy
Strong Buy
Analyst Count
11
12
Target Price
$209.73
$126.92
AVG Volume (30 Days)
843.5K
822.1K
Earning Date
04-21-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
2.56
N/A
EPS
0.82
N/A
Revenue
$131,300,000.00
$507,442,000.00
Revenue This Year
$8.10
$23.32
Revenue Next Year
$8.81
$27.43
P/E Ratio
$230.94
N/A
Revenue Growth
N/A
32.33
52 Week Low
$119.06
$73.16
52 Week High
$220.72
$184.00

Technical Indicators

Market Signals
Indicator
MANH
GKOS
Relative Strength Index (RSI) 67.82 72.12
Support Level $167.26 $94.16
Resistance Level $204.83 N/A
Average True Range (ATR) 8.81 7.62
MACD 3.69 0.52
Stochastic Oscillator 65.53 56.01

Price Performance

Historical Comparison
MANH
GKOS

About MANH Manhattan Associates Inc.

Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers worldwide.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: